Phaseline

Companies › Kodiak Sciences

Kodiak Sciences: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 3; Ophthalmology, Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KSI-101
IL-6 receptor antagonist (IL-6R-Fc fusion protein)
IL6RPhase 3Macular Edema Secondary to InflammationFeb 2027
Tabirafusp tedromer–Phase 3Wet Age-related Macular Degeneration; Diabetic Macular Edema (DME)Aug 2027
Tarcocimab tedromer
Monoclonal antibody against complement factor C3
C3Phase 3Wet Age-related Macular DegenerationAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06996080KSI-101Phase 3Macular Edema Secondary to InflammationImmunologyFeb 2027
NCT06990399KSI-101Phase 3Macular Edema Secondary to InflammationImmunologyApr 2027
NCT06556368Tarcocimab tedromerPhase 3Wet Age-related Macular DegenerationOphthalmologyAug 2027
NCT06556368Tabirafusp tedromerPhase 3Wet Age-related Macular DegenerationOphthalmologyAug 2027
NCT07734844Tabirafusp tedromerPhase 3Diabetic Macular Edema (DME)OphthalmologyAug 2028

From the company's SEC filings

Cash of $126m on 2026-06-30; operating cash outflow about $175m a year; runway about 9 months at that burn, to Mar 2027; 1 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

C3 (1) IL6R (1)

Companies with the same targets

Apellis Pharmaceuticals Annexon Beijing VDJBio Roche Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Shenyang Sunshine Pharmaceutical Swedish Orphan Biovitrum Biocad Johnson & Johnson (Janssen) Innovent Biologics (Suzhou)

Companies built like this

EyePoint Pharmaceuticals Santen Pharmaceutical Annexon Alcon Research SpyGlass Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.